Physician profile
Ashley Michelle Reader
NPI 1740638949
$14,968.27
in general payments reported to CMS, 2019-2025
34 companies · $3,427 in 2025
The $3,427 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $549 · 2021: $1,206 · 2022: $4,884 · 2023: $1,337 · 2024: $2,823 · 2025: $3,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,365 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,364.99 |
| Education | $222.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,670.30 | 2021-2022 | |
| Abbvie INC. | $2,502.11 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,066.05 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,007.10 | 2019-2025 | |
| Janssen Biotech, INC. | $792.40 | 2021-2025 | Tremfya |
| Ucb, INC. | $682.17 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $558.44 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $484.55 | 2023-2025 | Zoryve |
| Amgen INC. | $465.00 | 2020-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $447.88 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $445.62 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $381.22 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $370.03 | 2020-2025 | Nemluvio, Aklief |
| Pfizer INC. | $277.72 | 2019-2025 | |
| Leo Pharma INC. | $230.39 | 2021-2025 | Adbry |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $188.29 | 2021-2024 | Opzelura |
| Almirall LLC | $176.65 | 2022-2025 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.21 | 2024 | Spevigo |
| Biofrontera INC. | $164.63 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $159.98 | 2020-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $158.49 | 2020-2025 | Cabtreo, Siliq |
| Mayne Pharma Commercial LLC | $107.32 | 2025 | |
| Vyne Pharmaceuticals INC. | $99.64 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $75.00 | 2020 | |
| Epi Health, LLC | $61.65 | 2022 | |
| Journey Medical Corporation | $50.25 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $35.90 | 2024-2025 | Ycanth |
| Alnylam Pharmaceuticals INC. | $27.14 | 2024 | Givlaari |
| Organogenesis INC. | $23.81 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.13 | 2023 | |
| Next Science LLC | $20.00 | 2023 | Xperience, Blastx, Surgx |
| Botanix Sb INC | $14.62 | 2025 | Sofdra |
| Acera Surgical, INC. | $13.99 | 2022 | |
| Organon LLC | $13.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Reader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.